O-6-Methylguanine-DNA Methyltransferase (MGMT) Immunohistochemical Expression in Pituitary Corticotroph Adenomas
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
O-6-Methylguanine-DNA Methyltransferase (MGMT) Immunohistochemical Expression in Pituitary Corticotroph Adenomas
Authors
Keywords
-
Journal
NEUROSURGERY
Volume 70, Issue 2, Pages 491-496
Publisher
Oxford University Press (OUP)
Online
2011-08-05
DOI
10.1227/neu.0b013e318230ac63
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of Mismatch Repair and MGMT in Response to Anticancer Therapies
- (2012) Ida Casorelli et al. Anti-Cancer Agents in Medicinal Chemistry
- Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression
- (2010) Zachary M. Bush et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience
- (2010) Gérald Raverot et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- High incidence of low O6-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease
- (2009) Akira Takeshita et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Non-surgical management of hormone-secreting pituitary tumors
- (2009) Chirag G. Patil et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide
- (2009) Martin Glas et al. JOURNAL OF CLINICAL ONCOLOGY
- Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation WithMGMTPromoter Methylation Status
- (2009) Alba A. Brandes et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy
- (2008) B. Verbeek et al. BRITISH MEDICAL BULLETIN
- Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults
- (2008) S. Kesari et al. CLINICAL CANCER RESEARCH
- O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
- (2008) M. H. Kulke et al. CLINICAL CANCER RESEARCH
- Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours
- (2008) Ann I. McCormack et al. CLINICAL ENDOCRINOLOGY
- Treatment of Nelson's syndrome with temozolomide
- (2008) V J Moyes et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Pituitary-targeted medical therapy of Cushing's disease
- (2008) Krystallenia I Alexandraki et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity
- (2008) Monika E. Hegi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
- (2008) Michael D. Prados et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now